CANCER BIOLOGY PROGRAM Lisa M. Coussens, PhD, and Melissa Wong, PhD, Program Co-Leaders ABSTRACT Cancer Biology (CB) Program members explore genetic, molecular and cellular mechanisms underlying cancer initiation, progression, and response and resistance to therapy, providing platforms to translate basic science discoveries to clinical care. The program strives to gain insights into therapeutically-targetable pathways in neoplastic and host-derived cells within complex tumor microenvironments that drive malignancy. The program supports the overarching goal of the Knight Cancer Institute to understand the molecular and cellular basis of cancer and to translate these findings into precision clinical care. To accomplish these goals, the program is organized into three research themes: signal transduction (focused on cellular signaling mechanism relevant to homeostatic and neoplastic cell proliferation), carcinogenesis/genetic instability (examining cell intrinsic and extrinsic mechanisms that predispose to cancer, including regulation of cell-cycle checkpoint control, DNA damage and repair, and genetic and epigenetic alterations), and the tumor microenvironment (investigating mesenchymal support, immune, and vascular cell interactions with neoplastic cells). Program co-leader Melissa Wong, Ph.D., is an expert in stem cell biology, particularly in colorectal, breast and pancreas cancers. Co-leader Lisa M. Coussens, Ph.D., is an expert in the biology of microenvironmental regulation of solid tumorigenesis, with emphasis on cutaneous squamous, breast and pancreatic cancer. The 26 members are drawn from five basic science departments, three clinical departments or divisions in the OHSU School of Medicine, and four institutes affiliated with OHSU. Annual direct-cost funding as of January 2016 amounted to $14,666,464 (total cost), of which $6,250,223 (total cost) was from the NCI and $11,592,453 (total cost) was peer-reviewed. The discoveries made in this program have resulted in 202 publications, of which 12% are intra-programmatic collaborations and 28% are inter-programmatic collaborations, and 56% are inter-institutional.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA069533-19
Application #
9278528
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2017-07-01
Budget End
2018-06-30
Support Year
19
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Su, Yulong; Pelz, Carl; Huang, Tao et al. (2018) Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals. Genes Dev 32:1398-1419
Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828
Krey, Jocelyn F; Scheffer, Deborah I; Choi, Dongseok et al. (2018) Mass spectrometry quantitation of proteins from small pools of developing auditory and vestibular cells. Sci Data 5:180128
Rozanov, Dmitri V; Rozanov, Nikita D; Chiotti, Kami E et al. (2018) MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection. J Proteomics 176:13-23
Winters-Stone, Kerri M; Wood, Lisa J; Stoyles, Sydnee et al. (2018) The Effects of Resistance Exercise on Biomarkers of Breast Cancer Prognosis: A Pooled Analysis of Three Randomized Trials. Cancer Epidemiol Biomarkers Prev 27:146-153
Pennock, Nathan D; Martinson, Holly A; Guo, Qiuchen et al. (2018) Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. J Immunother Cancer 6:98
Xu, Li; Gordon, Ryan; Farmer, Rebecca et al. (2018) Precision therapeutic targeting of human cancer cell motility. Nat Commun 9:2454
Chen, Emerson Y; Blanke, Charles D; Haller, Daniel G et al. (2018) A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer. Am J Clin Oncol 41:1193-1198
Lane, Ryan S; Femel, Julia; Breazeale, Alec P et al. (2018) IFN?-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. J Exp Med 215:3057-3074
Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96

Showing the most recent 10 out of 277 publications